PTC Therapeutics, Inc. (NASDAQ:PTCT) announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the company’s application for a conditional marketing authorization of TranslarnaTM(ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older. PTC Therapeutics, Inc. (NASDAQ:PTCT) weekly performance is 32.91%. On last trading day company shares ended up $20.03. Analysts mean target price for the company is $38.33. PTC Therapeutics, Inc. (NASDAQ:PTCT) distance from 50-day simple moving average (SMA50) is -7.44%.
Novavax, Inc. (NASDAQ:NVAX) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced the appointment of Sven Andreasson to the position of Senior Vice President, Corporate Development, effective June 2, 2014. Mr. Andreasson will be responsible for identifying, prioritizing and evaluating new strategic opportunities that leverage the company’s core strengths and growth initiatives. Novavax, Inc. (NASDAQ:NVAX) shares advanced 7.06% in last trading session and ended the day on $4.85. Gross Margin is 60.80% and its return on assets is -30.90%. Novavax, Inc. (NASDAQ:NVAX) quarterly performance is -19.30%.
IsoRay Inc. (NYSEMKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced Isoray has received final approval from the State of Washington Department of Health to manufacture its recently FDA cleared Liquid Cesium-131 (Cesitrex®) for use with GliaSite® balloon catheter for the treatment of metastatic and glioblastoma brain cancers. IsoRay, Inc. (NYSEMKT:ISR) shares moved up 6.60% in last trading session and was closed at $2.26 , while trading in range of $2.10 – $2.37. IsoRay, Inc. (NYSEMKT:ISR) year to date (YTD) performance is 352.00%.
Shares of Orexigen Therapeutics Inc (NASDAQ:OREX) were the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 19,994,022 shares, an increase of 8.8% from the April 15th total of 18,376,599 shares, Analyst RN reports. Currently, 20.2% of the company’s stock are short sold. Based on an average daily volume of 1,999,972 shares, the short-interest ratio is currently 10.0 days. Orexigen Therapeutics, Inc. (NASDAQ:OREX) ended the last trading day at $5.71. Company weekly volatility is calculated as 5.44% and price to cash ratio as 4.28. Orexigen Therapeutics, Inc. (NASDAQ:OREX) showed a positive weekly performance of 6.53%.
Equities research analysts at Summer Street initiated coverage on shares of BioDelivery Sciences International Inc (NASDAQ:BDSI) in a research note issued to investors on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. Summer Street’s price objective suggests a potential upside of 130.15% from the company’s current price. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) weekly performance is 7.36%. On last trading day company shares ended up $9.33. Analysts mean target price for the company is $15.50. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) distance from 50-day simple moving average (SMA50) is 10.82%.